Close
Almac
Achema middle east

Clinical Trials

Achilles Teutics launched with funds of £13.2 million to develop Immunotherapies for Cancer

SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT) announce the formation of Achilles Therapeutics Ltd .The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and...

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

Thermo Fisher Scientific, the world leader in serving science announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides...

Sun Pharma announces the Phase 3 results of investigational psoriasis medicine

Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis at the 25th European Academy of Dermatology...

AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

AbbVie a global biopharmaceutical company announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed...

Genocea’s Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial

Genocea Biosciences, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies announced positive results from its ongoing Phase 2b trial evaluating a new Phase 3-ready formulation of GEN-003 for the treatment of genital herpes. The study...

Threshold Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities

Threshold Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products and technologies for the treatment of cancer, announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib Outlined...

Novartis announces AMG 334 significantly reduces monthly migraine days in people with episodic migraine

Novartis announced positive topline results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly subcutaneous AMG 334 (erenumab) 70mg in episodic migraine prevention. The study met the primary endpoint, demonstrating a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »